Apellis Pharmaceuticals and Beam Therapeuticsannounce 5-year research collaboration to apply Beam’s proprietary base-editing platform to six research programmes for tissues modulated by the complement system, including the eye, liver, and brain. The collaboration brings together Apellis’ complement expertise and Beam’s expertise in base editing.
Dublin-based ERS Genomics Limited and Japan-based Nippon Gene Co., Ltd announced a non-exclusive license agreement that sees Nippon Gene gain access to ERS Genomics’ CRISPR-Cas9 patent portfolio. Nippon Gene is a manufacturer of genetic engineering research reagents and diagnostic reagents for humans, animals, and plants, The deal will allow Nippon to develop, manufacture, and sell research reagents using CRISPR-Cas9 technology
A team of U.S. scientists has developed a CRISPR-based method with the goal of studying how eukaryotic cells repair DNA in space. The rationale behind the work is that astronauts travelling beyond outside the Earth’s magnetosphere are at an increased risk of DNA damage from ionising radiation. The new method uses Cas9 to create precise DNA breaks so that DNA repair pathways can be studied in more detail than would be possible using random DNA damage protocols such as radiation. The results were published in PLOS ONE this week.
A team at Brigham and Women’s Hospital (Boston) and collaborators has developed a designer yeast probiotic to help the management of inflammatory bowel disease. The probiotic was developed using CRISPR-Cas9 to introduce genes that could sense inflammation and respond to it by secreting an enzyme with anti-inflammatory activity. Preclinical results with the new probiotic, dubbed Y-bots' (yeast robots), were published in Nature Medicine this week.
CRISPR Tsunami: A 1-day introductory course to computational Cas9-gRNA design takes place virtually on 10th September 2021. The course is run by the University of Copenhagen, Denmark, doesn’t assume prior knowledge about gRNA design and is free of charge. Read more about it here.
CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies. This review summarises the various strategies for the treatment and study of molecular mechanisms of antimicrobial-resistant bacteria in the so-called ESKAPE group of pathogens (Enterococcus spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) based on CRISPR and related genome-editing technologies.
Fighting Cancer with CRISPR: A snappy 10 min video from Bloomberg TV explaining the transformation currently taking place in healthcare and biotech industries involving CRISPR.